Royal Bank of Canada’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-61
| Closed | -$1K | – | 7807 |
|
|
2024
Q1 | $1K | Buy |
+61
| New | +$405 | ﹤0.01% | 6931 |
|
|
2023
Q4 | – | Sell |
-1,209
| Closed | -$5K | – | 7908 |
|
|
2023
Q3 | $5K | Buy |
1,209
+597
| +98% | +$2.33K | ﹤0.01% | 6639 |
|
|
2023
Q2 | $3K | Buy |
612
+602
| +6,020% | +$1.9K | ﹤0.01% | 6824 |
|
|
2023
Q1 | $0 | Sell |
10
-28
| -74% | -$103 | ﹤0.01% | 7719 |
|
|
2022
Q4 | $0 | Sell |
38
-31
| -45% | -$119 | ﹤0.01% | 8034 |
|
|
2022
Q3 | $0 | Buy |
69
+35
| +103% | +$304 | ﹤0.01% | 8118 |
|
|
2022
Q2 | $0 | Sell |
34
-15
| -31% | -$136 | ﹤0.01% | 7987 |
|
|
2022
Q1 | $0 | Sell |
49
-766
| -94% | -$19.5K | ﹤0.01% | 8181 |
|
|
2021
Q4 | $39K | Buy |
815
+753
| +1,215% | +$79.1K | ﹤0.01% | 6517 |
|
|
2021
Q3 | $9K | Buy |
62
+18
| +41% | +$2.34K | ﹤0.01% | 7019 |
|
|
2021
Q2 | $5K | Sell |
44
-17
| -28% | -$1.9K | ﹤0.01% | 7090 |
|
|
2021
Q1 | $6K | Buy |
+61
| New | +$7.96K | ﹤0.01% | 7012 |
|
Royal Bank of Canada's LABP Position: Q2 2024 in Review
Royal Bank of Canada sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2024, closing a stake of 61 shares — an estimated $1K sold.
Royal Bank of Canada first reported a position in LABP in Q1 2021 and held it in 12 quarters. The position peaked at $39K in Q4 2021. 0 funds tracked by Wall St. Rank hold LABP as of Q2 2024.
- Royal Bank of Canada reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Royal Bank of Canada sold 61 Landos Biopharma, Inc. Common Stock shares in Q2 2024, an estimated $1K.
- Royal Bank of Canada first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
- Royal Bank of Canada's Landos Biopharma, Inc. Common Stock position peaked at $39K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2024.
Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.